進行期小細胞肺癌(ES-SCLC)患者を対象としたルルビネクテジンとデュルバルマブ併用療法に関する研究
白金系化学療法およびデュルバルマブによる導入療法後の広範期小細胞肺癌患者を対象とした、ルルビネクテジンとデュルバルマブ併用による第2相、多施設共同、非盲検、単群試験の初回維持療法
The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.
調査の概要
詳細な説明
The study will evaluate the safety and efficacy of lurbinectedin in combination with durvalumab as maintenance therapy in participants with ES-SCLC after first line induction therapy with durvalumab and platinum plus etoposide containing regimen. In order to be considered for eligibility screening for the maintenance phase, participants need to have an ongoing CR, PR, or stable disease (SD) per RECIST v1.1 criteria after completion of 4 cycles of platinum plus etoposide containing regimen with at least 3 cycles of durvalumab during induction treatment.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Clinical Trial Disclosure & Transparency
- 電話番号:215-832-3750
- メール:ClinicalTrialDisclosure@JazzPharma.com
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90067
- 募集
- Valkyrie Clinical Trials, Inc.
-
-
Florida
-
Jacksonville、Florida、アメリカ、32256
- 募集
- Cancer Specialists of North Florida
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- 募集
- Emory University
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40503
- 募集
- Baptist Health
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64132
- 募集
- MidAmerica Cancer Centre
-
-
South Carolina
-
Rock Hill、South Carolina、アメリカ、29732
- 募集
- Carolina Blood and Cancer Care
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participant has histologically or cytologically confirmed ES-SCLC (per Veterans Administration Lung Study Group staging system).
- Participant has received 4 cycles of definitive platinum-based chemotherapy with at least 3 cycles of durvalumab
- Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
- Must have a life expectancy of ≥ 12 weeks as assessed by the treating physician.
- Adequate hematologic and end-organ function for at least 7 days prior to dosing.
- Has a body weight > 30 kg.
- Adequate contraceptive precautions.
Exclusion Criteria:
- Clinically confirmed leptomeningeal carcinomatosis.
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
- Significant cardiovascular disease within 3 months prior to enrollment
- History of another primary malignancy
- Presence or history of Central Nervous System (CNS) metastases
- History of allogeneic organ transplantation.
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on the screening chest CT scan.
- Any concurrent chemotherapy, study intervention, biologic, or hormonal therapy for cancer treatment.
- Receipt of live attenuated vaccine within 30 days prior to the first dose of study intervention.
- Pregnant or breastfeeding or intending to become pregnant during the study or within 6 months after the last dose of study intervention.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Durvalumab and lurbinectedin treatment arm
Durvalumab taken in combination with lurbinectedin in participants with ES-SCLC after first line induction therapy with durvalumab and platinum plus etoposide containing regimen. |
Administered by intravenous (IV) infusion
他の名前:
Administered by intravenous (IV) infusion
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Investigator assessed PFS rate
時間枠:6 months
|
Progression Free Survival (PFS) rate is the proportion of participants who have not experienced disease progression (as determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1) or death from any cause |
6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
投与量調整が必要な参加者数
時間枠:最大2年間
|
最大2年間
|
|
|
併用療法のいずれかの構成要素の中止を必要とした参加者数
時間枠:最大2年間
|
最大2年間
|
|
|
ルビネクテジンの血漿中濃度
時間枠:最大3か月
|
最大3か月
|
|
|
Investigator assessed PFS
時間枠:Up to 2 years
|
PFS is defined as the time from the start of maintenance treatment until the first documentation of disease progression (as determined by the investigator according to RECIST v1.1) or death due to any cause, whichever occurs first. |
Up to 2 years
|
|
Investigator-assessed confirmed ORR
時間枠:Up to 2 years
|
Confirmed Objective Response Rate (ORR) is the proportion of participants with Complete Response (CR) or Partial Response (PR) on 2 consecutive occasions ≥ 4 weeks apart, after the start of maintenance treatment, as determined by the investigator according to RECIST v1.1. |
Up to 2 years
|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
時間枠:First dose to 90 days after last dose (Up to 2 years)
|
Assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 or higher |
First dose to 90 days after last dose (Up to 2 years)
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- JZP712-203
- 2025-524566-13-00 (Ctis)
- 2025 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
In accordance with ICMJE requirements, Jazz Pharmaceuticals may provide qualified external researchers access to individual participant data (IPD) and clinical trial data that underlie the results of this trial upon request. Qualified researchers can submit a request on https://www.jazzpharma.com/science/clinical-trial-data-sharing/ as outlined. Jazz Pharmaceuticals reserves the right not to consider a request. For inquiries about Jazz's data sharing policy contact clinicaldatasharing@jazzpharma.com.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。